Tomorrow 79-80,by Monday morning sale announced to be 150
I think as long as it stays at these prices or goes below 70 to add to your position. A year from now it will be North of $150 on its own. That is why I say a takeover has to be over $8 billion otherwise the acquiring company is stealing it at what ever price they get it for. Don't believe the hype that the PARP market is crowded it is just nonsense since we are at the infancy of treating regimens being designed to use PARPs for a variety of cancers.
Looks like recovering well...
here we go!
I was looking for some type of confirmation that maybe Lilly is interested in Clovis. The October 27 puts with a strike price of 75 are much more active than any other put or call for that matter. Someone or some people feel Lilly will be below 75 by the end of October and that is taking into consideration the positive news that has come out lately on Lilly. Taking on debt or issuing more shares to finance a takeover could be the reason. Maybe there is some truth to the pending LLY-CLVS takeover.
Any serious buyout talk should start at $8 billion and nothing less. If this company gets sold for $6 billion it will be the steal of the century. Just saying....GLTA longs
After hours buyout announcements coming!!! The big boys got prior leaks already.
oh man, I sold half at 71 this morning... so mad... well, at least i still have 1/2
I would not be surprise if after all, Clovis turns out to be the big winner of all. Potentially creating a bidding war among the big pharma players such as Gilead, Elly, etc......I can think of so many companies that will benefit from this buyout. Even at current level, Clovis still cheap.......over half of Billions in cash, little debt and lable expansion on the way.
The simple rule: any company with an approved oncology drug is a $3B+ company. The PARPi field is wide opened since Ovarian cancer (OC) monotherapy is just a beginning with various other cancers (prostate, breast, lung, etc) and combos to follow. GILD just paid for KITE a fortune. CAR-T science is not there with the commercially unattractive drug administration. Finally, CAR-T drugs are extremely toxic making marketing a very tricky business.
Nice volume at the $110 strike
what happened ?
I do not see takeover price at $110 dollars. That is way to cheap, a the company has $500 million in cash to spend on studies and marketing. Nothing less than $8 billion in a takeover which is about $155 per share. Negotiations take time so don't expect the deal to be consummated today. Mid October more likely.
Takeover rumor du jour: Clovis by Lilly
Clovis Oncology (CLVS +6.1%) perks up on light volume amidst chatter that Eli Lilly (LLY -0.3%) is mulling a bid.The company recently announced positive results from a late-stage study assessing lead
Here comes the squeezed 💪
Crossing the 80 $ mark will be a positive sign that we are indeed heading north...
1r0 to 155
Buyout is inevitable. They have the best-in-class drug. They are also the cheapest compared to competitors. Perfect combination.